---
title: "Bioline RX：2025 全年业绩"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/280217686.md"
description: "BioLineRx Ltd.（纳斯达克代码：BLRX）公布了其 2025 财务业绩，显示许可收入为 120 万美元，净运营亏损为 1030 万美元。该公司宣布与 Hemispherian 的合资企业 Tetragon Biosciences 计划在 2026 年 3 月底之前开始对胶质母细胞瘤患者进行筛查"
datetime: "2026-03-23T21:27:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280217686.md)
  - [en](https://longbridge.com/en/news/280217686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280217686.md)
---

# Bioline RX：2025 全年业绩

By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported 2025 financial and operational results in a March 23rd, 2026, press release. For the year, it produced license revenues of $1.2 million and a net operating loss of $10.3 million. The joint venture (JV) with Hemispherian, called Tetragon Biosciences, expects to begin screening patients by the end of this month for the glioblastoma...

### 相关股票

- [BLRX.US](https://longbridge.com/zh-CN/quote/BLRX.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)

## 相关资讯与研究

- [定义 “医院 AI 操作系统”：北协和、南湘雅等顶级医院 为何集体选择医渡科技？](https://longbridge.com/zh-CN/news/286870257.md)
- [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md)
- [SpaceX 选择纳斯达克作为其 IPO 的上市场所](https://longbridge.com/zh-CN/news/286604046.md)
- [报道：SpaceX 加速 IPO 时间表，目标 6 月 11 日在纳斯达克定价](https://longbridge.com/zh-CN/news/286602881.md)
- [Cerebras 纳斯达克首秀开盘价 350 美元 创 2026 年最大 IPO 纪录](https://longbridge.com/zh-CN/news/286456474.md)